Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

therabel pharma sa-nv - molsidomine 2 mg/ml - concentrate for solution for infusion - 20 mg/10 ml - molsidomine 20 mg - molsidomine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

therabel pharma sa-nv - levodropropizine 0,6 g/100 ml - syrup - 6 mg/ml - levodropropizine 6 mg/ml - levodropropizine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

therabel pharma sa-nv - warfarin sodium 5 mg - eq. warfarin 4,67 mg - tablet - 5 mg - warfarin sodium 5 mg - warfarin

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

therabel pharma sa-nv - molsidomine 16 mg - prolonged-release tablet - 16 mg - molsidomine 16 mg - molsidomine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

therabel pharma sa-nv - neomycin sulfate 10 mg/ml; dexamethasone sodium metasulfobenzoate 1 mg/ml; polymyxin b sulfate 10000 iu/ml - ear drops, solution - 10 mg/ml - 10000 iu/ml - 1 mg/ml - dexamethasone sodium metasulfobenzoate 1 mg/ml; neomycin sulfate 6500 iu/ml; polymyxin b sulfate 10000 iu/ml - dexamethasone and antiinfectives

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

therabel pharma sa-nv - serenoa repens (bartram) small, fruit, lipophilic extract 320 mg - capsule, hard - 320 mg - sabal serrulata (serenoa repens), lipophilic extract by co2 320 mg - sabalis serrulatae fructus

Australia - English - Department of Health (Therapeutic Goods Administration)

ikaria australia pty ltd - 46913 - photopheresis system blood set - therakos? cellex? photopheresis system procedural kit is indicated for extracorporeal photopheresis (single use)

Australia - English - Department of Health (Therapeutic Goods Administration)

ikaria australia pty ltd - methoxsalen, quantity: 0.2 mg - injection, concentrated - excipient ingredients: ethanol; glacial acetic acid; propylene glycol; sodium acetate trihydrate; sodium chloride; water for injections; sodium hydroxide - uvadex (methoxsalen) is indicated for extracorporeal administration with the therakos cellex photopheresis system for the: ? treatment of steroid-refractory and steroid-intolerant chronic graft versus host disease (cgvhd) in adults following allogeneic hsc transplantation. ? palliative treatment of the skin manifestations of cutaneous t-cell lymphoma (ctcl) that is unresponsive to other forms of treatment.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - etodolac (unii: 2m36281008) (etodolac - unii:2m36281008) - etodolac 400 mg - carefully consider the potential benefits and risks of etodolac extended-release tablets and other treatment options before deciding to use etodolac extended-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). etodolac extended-release tablets are indicated: - for relief of signs and symptoms of juvenile arthritis. - for relief of the signs and symptoms of rheumatoid arthritis. - for relief of the signs and symptoms of osteoarthritis. etodolac extended-release tablets are contraindicated in patients with known hypersensitivity to etodolac. etodolac extended-release tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactoid reactions and precautions, preexisting asthma ). etodolac extended-release tablets are contr

United States - English - NLM (National Library of Medicine)

lake erie medical & surgical supply dba quality care products llc - etodolac (unii: 2m36281008) (etodolac - unii:2m36281008) - etodolac 500 mg - carefully consider the potential benefits and risks of etodolac extended-release tablets and other treatment options before deciding to use etodolac extended-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). etodolac extended-release tablets are indicated: - for relief of signs and symptoms of juvenile arthritis. - for relief of the signs and symptoms of rheumatoid arthritis. - for relief of the signs and symptoms of osteoarthritis. etodolac extended-release tablets are contraindicated in patients with known hypersensitivity to etodolac. etodolac extended-release tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactoid reactions and precautions, preexisting asthma ). etodolac extended-release tablets are contr